Agreements signed with three new partners, bringing the total number of new AAV customers in 2022 to four, ahead of original target Oxford, UK – 14 December 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that its subsidiary Oxford Biomedica… Read More
Oxford, UK – 22 November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces the appointment of Dr Frank Mathias as Chief Executive Officer (CEO) and Board Director, effective March 2023. Dr Mathias brings world-class innovation and contract development and manufacturing… Read More
Oxford, UK – 14 November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces exchange of contracts for the sale of its Windrush Court facility (the “Property”) to Kadans Science Partner (“Kadans”) for £60 million. Completion is due to occur… Read More
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More
Significant strategic and operational progress towards becoming a global viral vector leader Oxford, UK – 15 September 2022: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2022. Roch Doliveux, Oxford Biomedica’s… Read More
Oxford, UK – 14 September 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that its subsidiary Oxford Biomedica Solutions LLC (“Oxford Biomedica Solutions”), a high-performing full-scope scope AAV manufacturing and innovation business, has signed an agreement with a new… Read More
Oxford, UK – 7 September 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with an undisclosed US-based late-stage cell and gene therapy company. The LSA grants the new… Read More
Oxford, UK – 16 August 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, notes the release of Homology Medicines’ (“Homology”) quarterly report for the three months ended 30 June 2022. Financial information on Oxford Biomedica Solutions LLC (“Oxford Biomedica Solutions”) contained… Read More
Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with an undisclosed US-based private biotechnology company advancing a new generation of adoptive cell therapies. The… Read More
Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new project with Orchard Therapeutics utilising the Company’s proprietary LentiStable™ technology. As part of the project, Oxford Biomedica’s LentiStable™ technology platform… Read More
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More